产品订购信息：
英文名称  Anti-RelB 

中文名称   转录因子RelB蛋白抗体费用 

别    名  I REL; IREL; Nuclear factor of kappa light polypeptide gene enhancer in B cells 3; RelB; Reticuloendotheliosis viral oncogene homolog B; Transcription factor RelB; v rel avian reticuloendotheliosis viral oncogene homolog; v rel reticuloendotheliosis viral oncogene homolog B; RELB_HUMAN; I-Rel.

浓    度   1mg/1ml

规 格  0.2ml/200μg

抗体来源   Rabbit

克隆类型   polyclonal

交叉反应   Human, Mouse, Rat, Dog, Pig, Cow, Horse 

产品类型   一抗  

研究领域     免疫学 信号转导 细胞凋亡 转录调节因子

蛋白分子量  predicted molecular weight: 64kDa

性    状   Lyophilized or Liquid

免 疫 原 KLH conjugated synthetic peptide derived from human RelB 

亚    型   IgG

纯化方法   affinity purified by Protein A

储 存 液   0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide

转录因子RelB蛋白抗体费用 产品应用    WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500

（石蜡切片需做抗原修复） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存条件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

产品介绍 The NFKB complex consists of NFKB1 or NFKB2 bound to REL, RELA, or RELB. The NFKB complex is inhibited by I kappa B proteins (NFKBIA, or NFKBIB), which inactivate NF kappa B by trapping it in the cytoplasm. Phosphorylation of serine residues on the I kappa B proteins by kinases (IKBKA, or IKBKB,) marks them for destruction via the ubiquitination pathway, thereby allowing activation of the NF kappa B complex.

Function : NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment.

Subunit : Component of the NF-kappa-B RelB-p50 complex. Component of the NF-kappa-B RelB-p52 complex. Self-associates; the interaction seems to be transient and may prevent degradation allowing for heterodimer formation with p50 or p52. Interacts with NFKB1/p50, NFKB2/p52 and NFKB2/p100. Interacts with NFKBID.

Subcellular Location : Nucleus. Cytoplasm, cytoskeleton, centrosome. Note=Co-localizes with NEK6 in the centrosome.

Post-translational modifications : Phosphorylation at 'Thr-103' and 'Ser-573' is followed by proteasomal degradation.

Similarity : Contains 1 RHD (Rel-like) domain.

Database links : UniProtKB/Swiss-Prot: Q01201.2

NOS-2 peptide 合成酶-2多肽抗原Multi-class antibodies规格： 0.5mg

Anti-AQP2 水通道蛋白-2抗体Multi-class antibodies规格： 0.1ml

Rhesus antibody Rh phospho-ATG7(Ser95) 磷酸化自噬相关蛋白7抗体 规格 0.1ml

山羊抗人 IgM/HRP 0.1ml 美国Jackson公司分装

Viperin 英文名称： 病毒抑制蛋白Viperin抗体 0.2ml

Dio3 英文名称： 甲状腺素5'脱酶3抗体 0.1ml

Anti-AQP2 水通道蛋白-2抗体Multi-class antibodies规格： 0.1ml

Anti-IL-16/FITC 荧光素标记白介素16抗体IgGMulti-class antibodies规格： 0.2ml

Rabbit Anti-human sIgA/FITC 荧光素标记兔抗人分泌型IgA抗体Multi-class antibodies规格： 0.2ml

Rhesus antibody Rh Apg12 自噬相关蛋白12抗体 规格 0.2ml

Rabbit Anti-rat IgG/RBITC 罗丹明标记的兔抗大鼠IgG 0.3ml

GIMAP6 英文名称： GTP酶IMAP家族成员6抗体 0.2ml

Rhesus antibody Rh Rabbit Anti-human sIgA/Alexa Fluor 350 Alexa Fluor 350标记的兔抗人分泌型IgA 规格 0.1ml

Rabbit Anti-human sIgA/FITC 荧光素标记兔抗人分泌型IgA抗体Multi-class antibodies规格： 0.2ml

SIRT3 英文名称： 线粒体乙酰化酶3抗体 0.2ml

EphB2 英文名称： 酪酸蛋白激酶受体B2抗体 0.1ml

Caspase 激活的脱氧核糖核酸酶抗体 Anti-CAD/CPAN 0.1ml

Anti-Phospho-Tuberin/TSC2 (Tyr1571)/FITC 荧光素标记磷酸化马铃薯球蛋白(性硬化)抗体IgGMulti-class antibodies规格： 0.2ml

Rhesus antibody Rh Phospho-HSP27(Ser78) 磷酸化热休克蛋白27抗体 规格 0.1ml

cath-B/CB(Cathepsin B) 组织蛋白酶B抗原Multi-class antibodies规格： 0.5mg

正常细胞

CAM191 EBV-转化人淋巴细胞

CD4 Others Human 人 CD4 / LEU3 (aa 1-208) 人细胞裂解液 (阳性对照)

CL-0094HCC827(人非小细胞细胞)5×106cells/瓶×2

人少突胶质前体细胞-悬浮生长裂解物HOPC-os L

人原胚肾转化细胞;293 Ad5 人脐内皮细胞完全培养基 100mL

CL-0106HFL1(人)5×106cells/瓶×2

KIR2DL4 Others Human 人 KIR2DL4 / CD158D CHO细胞裂解液 (阳性对照)

人表皮黑色素细胞-浅色素裂解物HELM-l L

新生牛眼晶体上皮细胞;NBLE 人细胞，SW579细胞 RIN-m5F细胞，小鼠β瘤细胞

人膀胱上皮永生化细胞;SV-HUC-1

EPHA4 Others Human 人 EPHA4 人细胞裂解液 (阳性对照)

转录因子RelB蛋白抗体费用 正常细胞

CAM191 EBV-转化人淋巴细胞

CD4 Others Human 人 CD4 / LEU3 (aa 1-208) 人细胞裂解液 (阳性对照)

CL-0094HCC827(人非小细胞细胞)5×106cells/瓶×2

人少突胶质前体细胞-悬浮生长裂解物HOPC-os L

人原胚肾转化细胞;293 Ad5 人脐内皮细胞完全培养基 100mL

抗体的生物素化标记实验要点：

1. 转录因子RelB蛋白抗体费用 如在反应混合液中有叠氮钠或游离氨基存在,会抑制标记反应。因此,蛋白质在反应前要对 0.1mol/L碳酸氢钠缓冲液或0.5mol/L硼酸缓冲液充分透析；

2.所用的NHSB及待生物素化蛋白质之间的分子比按蛋白质表面的ε-氨基的密度会有所不同,选择不当则影响标记的效率,应先用几个不同的分子比来筛选最适条件；

3.用NHSB量过量也是不利的,抗原的结合位点可能因此被封闭,导致抗体失活；

4.由于抗体的氨基不易接近可能造成生物素化不足,此时可加入去污剂如 Triton x-100, Tween20等；

5.当游离ε-氨基(赖氨酸残基的氨基)存在于抗体的抗原结合位点时,或位于酶的催化位点时,生物素化会降低或损伤抗体蛋白的结合力或活性；

6.生物素还可能与不同的功能基团,如羰基、氨基、巯基、异咪唑基及苯酚基,也可与糖基共价结合；

7.交联反应后,应充分透析,否则,残余的生物素会对生物素化抗体与亲和素的结合产生竞争作用；

8.在细胞的荧光标记实验中,中和亲和素的本底低,但由于链霉亲和素含有少量正电荷,故对某些细胞可导致高本底。

抗体的鉴定：

1）转录因子RelB蛋白抗体费用 抗体的效价鉴定：不管是用于诊断还是用于,制备抗体的目的都是要求较高效价。不同的抗原制备的抗体,要求的效价不一。鉴定效价的方法很多,包括有试管凝集反应,琼脂扩散试验,酶联免疫吸附试验等。常用的抗原所制备的抗体一般都有约成的鉴定效价的方法,以资比较。如制备抗抗体的效价,一般就采用琼脂扩散试验来鉴定。

2）抗体的特异性鉴定：抗体的特异性是指与相应抗原或近似抗原物质的识别能力。抗体的特异性高,它的识别能力就强。衡量特异性通常以交叉反应率来表示。交叉反应率可用竞争抑制试验测定。以不同浓度抗原和近似抗原分别做竞争抑制曲线,计算各自的结合率,求出各自在IC50时的浓度,并按公式计算交叉反应率。 

如果所用抗原浓度IC50浓度为pg/管,而一些近似抗原物质的IC50浓度几乎是无穷大时,表示这一抗血清与其他抗原物质的交叉反应率近似为0,即该血清的特异性较好。

3）抗体亲和力：是指抗体和抗原结合的牢固程度。亲和力的高低是由抗原分子的大小,抗体分子的结合位点与抗原决定簇之间立体构型的合适度决定的。有助于维持抗原抗体复合物稳定的分子间力有氢键,疏水键,侧链相反电荷基因的库仑力,范德华力和空间斥力。亲和力常以亲和常数K表示,K的单位是L/mol。抗体亲和力的测定对抗体的筛选,确定抗体的用途,验证抗体的均一性等均有重要意义。